Caudill Cortney 4

What Happened

• Cortney Caudill, COO of Halozyme Therapeutics (HALO), exercised stock options to acquire 21,546 shares at $33.51 per share (total cash outlay ~ $722,006). The filing also shows Caudill sold a total of 28,857 shares in open-market transactions for aggregate proceeds of about $1,955,159. The Form 4 lists matching derivative dispositions for the exercised amounts, indicating the exercised shares were promptly disposed (same-day sale/cashless-style treatment).

Key Details

• Transaction dates: March 9, 2026 (major exercise and sales) and March 10, 2026 (small exercise and sale).
• Options exercised: 20,000 shares on 3/9 and 1,546 shares on 3/10 at $33.51 each (total ~ $722,006).
• Open-market sales: 17,900 shares @ weighted avg $67.75; 2,100 shares @ weighted avg $68.25; 8,857 shares @ weighted avg $67.64 — combined proceeds ≈ $1.955M. (Footnotes show sale price ranges across those lots; issuer can provide per-price breakdown on request.)
• Filing timeliness: Report filed 2026-03-10 for transactions on 2026-03-09 and 2026-03-10 — appears timely.
• Footnote on options: Options were granted Nov 1, 2023 and vest over 4 years (25% after 12 months, then monthly thereafter).

Context

• Derivative code M = option exercise; S = open-market sale. The filing’s matching acquisition and derivative-disposition entries suggest the exercised shares were immediately sold (cashless or to cover exercise/taxes), rather than being retained as a net long position. Purchases (exercises) and sales occurred on consecutive days; total cash received from open-market sales exceeded the cash paid to exercise the options.
• The filing is factual and does not state motivation. For post-transaction beneficial ownership (shares held after these trades) or exact per-lot sale prices, consult the full Form 4 (accession 0001159036-26-000033).